-+ 0.00%
-+ 0.00%
-+ 0.00%

PMV Pharma Q1 FY26 net loss widens to $18 million

PUBT·05/12/2026 12:01:56
Listen to the news
PMV Pharma Q1 FY26 net loss widens to $18 million
  • PMV Pharmaceuticals posted a net loss of USD 18 million for first-quarter 2026, widening from USD 17.4 million a year earlier.
  • R&D expense fell 12.07% to USD 15.3 million, G&A costs dropped 9.76% to USD 3.7 million.
  • Cash, cash equivalents, and marketable securities slid to USD 93.5 million as of March 31, 2026, from USD 112.9 million at year-end 2025; net cash used in operations rose to USD 19.7 million from USD 18.3 million a year earlier.
  • FDA granted orphan drug designation to rezatapopt for TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers; Phase 1 rezatapopt data were published in New England Journal of Medicine.
  • Management said enrollment remains on track in PYNNACLE Phase 2, keeping rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer targeted for first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-218225), on May 12, 2026, and is solely responsible for the information contained therein.